SHC vs the Top Picks average
| Pillar | SHC | Book avg | Diff |
|---|---|---|---|
| Quality | 0.62 | 0.84 | -0.22 |
| Growth | 0.77 | 0.84 | -0.07 |
| Value | 0.68 | 0.78 | -0.11 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | +1.4% |
|---|---|
| 90-day change | +1.4% |
| Forward EPS estimate | $1.07 |
Over the last 90 days, what analysts expect SHC to earn is drifting higher (+1.4%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Sotera Health Company (SHC): score, valuation & FAQ
Sotera Health Company (SHC) is a Diagnostics & Research company that scores 68.4 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
The model flags D/E (D) as weaker areas. On valuation, SHC sits about 374% above our discounted-cash-flow fair value — the current price implies roughly 51% annual free-cash-flow growth over the next decade.
Is SHC a good stock to buy?
Bull Rankings scores SHC 68.4 out of 100 on its quality-growth model, which is a solid, above-average reading. A score is a quantitative screen of Sotera Health Company's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does SHC score 68.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). SHC grades middle-of-pack across the strip, and is held back by D/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is SHC overvalued or undervalued?
Based on $19.57, SHC sits about 374% above our discounted-cash-flow fair value — the current price implies roughly 51% annual free-cash-flow growth over the next decade. It trades at a 34.3x P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in SHC?
D/E 3.41 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.77 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.